G

Gentian Diagnostics ASA
OSE:GENT

Watchlist Manager
Gentian Diagnostics ASA
OSE:GENT
Watchlist
Price: 57.2 NOK 1.42% Market Closed
Market Cap: 882m NOK

Net Margin
Gentian Diagnostics ASA

25.8%
Current
-3%
Average
1.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
25.8%
=
Net Income
42.2m
/
Revenue
163.4m

Net Margin Across Competitors

No Stocks Found

Gentian Diagnostics ASA
Glance View

Market Cap
882.2m NOK
Industry
Health Care

Gentian Diagnostics ASA is a medical diagnostics company. The company is headquartered in Moss, Ostfold. The company went IPO on 2016-12-14. The firm develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The firm is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.

GENT Intrinsic Value
45.66 NOK
Overvaluation 20%
Intrinsic Value
Price
G
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
25.8%
=
Net Income
42.2m
/
Revenue
163.4m
What is the Net Margin of Gentian Diagnostics ASA?

Based on Gentian Diagnostics ASA's most recent financial statements, the company has Net Margin of 25.8%.

Back to Top